Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma (TIL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT00200577
First received: September 12, 2005
Last updated: January 30, 2013
Last verified: January 2013

September 12, 2005
January 30, 2013
May 2005
December 2012   (final data collection date for primary outcome measure)
  • Determination of the duration of the relapse-free interval. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Physical examination, every 2 months until M18 then every 3 months until M36 then every 4 months up to 5 years, then once per year with a clinical examination only. [ Time Frame: every 2 months until M18then every 3 months until M36 then every 4 months up to 5 years ] [ Designated as safety issue: No ]
  • Abdominal echography will be performed at the screening visit, M4, M8, M12 and then every 6 months until 5ans. [ Time Frame: M4, M8, M12 and then every 6 months until 5ans. ] [ Designated as safety issue: No ]
  • CT-Scan will be performed before the first administration of study treatment (at the time of screening visit), every 6 months during 2 years and then every years up to 5 years. [ Time Frame: every 6 months during 2 years and then every years up to 5 years. ] [ Designated as safety issue: No ]
  • -Determination of the duration of the relapse-free interval.
  • -physical examination, every 2 months until M18 then every 3 months until M36 then every 4 months up to 5 years, then once per year with a clinical examination only.
  • -Abdominal echography will be performed at the screening visit, M4, M8, M12 and then every 6 months until 5ans.
  • -CT-Scan will be performed before the first administration of study treatment (at the time of screening visit), every 6 months during 2 years and then every years up to 5 years.
Complete list of historical versions of study NCT00200577 on ClinicalTrials.gov Archive Site
  • Determine of overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To define safety and toxicity of TIL/IL2 treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Evaluation of immunological responses [ Time Frame: M0, J56, M12 ] [ Designated as safety issue: No ]
  • Analysis of the clinical, biological and histological factors on the survival of the patients [ Time Frame: at inclusion and each month ] [ Designated as safety issue: Yes ]
  • - Determine of overall survival
  • - To define safety and toxicity of TIL/IL2 treatment
  • - Evaluation of immunological responses
  • - Analysis of the clinical, biological and histological factors on the survival of the patients
Not Provided
Not Provided
 
Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma
TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision

The objective of this multicentric Phase III study is to confirm the results of the phase I-II study (Dreno B & Al. Cancer Immunol Immunother 2002; 51: 539-456) which demonstrated the preventive effect of a treatment by TIL (Tumor Infiltrating Lymphocytes) combined with IL2 (Interleukin 2; low dose injected subcutaneously) on the metastatic relapse in the stage III melanoma patients with only one invaded lymphnode.

In this open, multicentric (Grenoble, Montpellier, Nantes, Angers, Caen, Le Mans, Poitiers, Rennes, Tours) randomized study, selected patients with only one invaded lymphnode confirmed by anatomopathological exam will be randomized to one of the following arms: 1-Control group: patients of this group will not receive any treatment and will have the same clinical follow-up as the treated group. 2- TIL-IL2 group: treated patients will receive two injections of TIL combined with IL2. Tumor Infiltrating Lymphocytes will be obtained from a small piece of tumour tissue removed from the invaded lymphnode after surgery. TIL will be grown in larger number in laboratory during 6 weeks. Patients randomized in treatment arm will receive two injection of TIL (the first about 6 and the second about 10 weeks post-surgery). Administration of TIL will be combined with a low dose of IL2 (6 million U.I. per day) injected subcutaneously from J1 to J5 and J8 to J12 following the day of TIL infusion. The same dose and duration of IL2 treatment will be used for the second injection of TIL performed one month later. After 2 months adjuvant therapy, patients received no other treatment. Only a regular follow-up was performed.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma
Drug: TIL + IL2
Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
  • Experimental: TIL+IL2
    TIL + IL2
    Intervention: Drug: TIL + IL2
  • No Intervention: control
    Patients are not treated
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Melanoma stage III (regional lymph node recurrence). Will be selected the patients with only one invaded lymph node confirmed by anatomopathological exam after lymph nodes excision.
  • Absence of visceral metastases verified by physical examination, chest radiography, liver echography and brain-chest-liver CT-Scan.
  • Age < 75 years, both genders
  • ECOG 0-2, Karnofsky > 80%.
  • Negative pregnancy test performed at the screening visit for fertile women.
  • The potentially fertile women must use an oral contraception or an intra-uterine device (IUD) until three months following the last injection of the study treatment.
  • The patients must have fully recovered from surgery.
  • HIV 1/2: The patients must be negative for antibodies HIV 1 and HIV 2 and for Ag P24 or DGV HIV.
  • HBV: The patients must be negative for the antigen, but can be positive for the antibodies but with a negative DNA PCR.
  • HCV: The patients must be negative for the antibodies.
  • HTLV ½: The patients must be negative for the antibodies.
  • Following laboratory results:

    • Hemoglobin: ≥ 10 g/dl
    • WBC: ≥ 4000/µl
    • Lymphocytes: ≥ 700/µl
    • Platelet count: ≥ 100.000/µl
    • Serum creatinine: < 2.0 mg/dl or £ 177 mmol/l
    • Serum Bilirubin: < 2.0 mg/dl or £ 34.2 mmol/l
    • ASAT and ALAT: < 2.5 x the upper limit of normal.

Exclusion criteria:

  • Patient with more than one invaded lymph node confirmed by anatomopathological exam.
  • Presence of melanoma metastases discovered by clinical or radiological examination at the screening visit.
  • Patients must not have received any Chemotherapy, immunotherapy or radiotherapy within the preceding 4 weeks (6 weeks since prior nitrosurea and mitomycin C therapies).
  • Presence of cardiac affections (congestive cardiac insufficiency, coronaropathy, not controlled HTA).
  • Any serious active medical illnesses, for example: Active systemic infections requiring of antibiotics, coagulation disorders or any other condition which requires concomitant medications not allowed during this study.
  • Presence of the second active cancer other than surgically cured non-melanoma skin cancer or cervical carcinoma in-situ.
  • Any affection requiring a systemic corticotherapy or a treatment by Interferon A.
  • Any active auto-immune disease including the insulin-dependent diabetes or a immunodeficiency. The vitiligo is not an exclusion criteria.
  • Thyroid dysfunction not responsive to therapy.
  • Positive Serology for HIV, HVB, HVC or HTLV1/2.
  • Woman pregnant or nursing or without an effective contraception.
  • Incapacity to give written consent.
Both
up to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00200577
BRD/04/1-D
No
Nantes University Hospital
Nantes University Hospital
Not Provided
Principal Investigator: Brigitte DRENO, MD Nantes University Hospital
Nantes University Hospital
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP